KR20100121352A - A composition comprising complex crude drug extract for anti-aging and improvement of skin - Google Patents
A composition comprising complex crude drug extract for anti-aging and improvement of skin Download PDFInfo
- Publication number
- KR20100121352A KR20100121352A KR1020090040461A KR20090040461A KR20100121352A KR 20100121352 A KR20100121352 A KR 20100121352A KR 1020090040461 A KR1020090040461 A KR 1020090040461A KR 20090040461 A KR20090040461 A KR 20090040461A KR 20100121352 A KR20100121352 A KR 20100121352A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- skin
- extract
- grape seed
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 113
- 239000000284 extract Substances 0.000 title claims abstract description 33
- 230000003712 anti-aging effect Effects 0.000 title abstract description 5
- 230000006872 improvement Effects 0.000 title description 9
- 239000003814 drug Substances 0.000 title description 2
- 229940079593 drug Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 51
- 244000269722 Thea sinensis Species 0.000 claims abstract description 39
- 230000009759 skin aging Effects 0.000 claims abstract description 37
- 241000508269 Psidium Species 0.000 claims abstract description 31
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 31
- 235000009569 green tea Nutrition 0.000 claims abstract description 30
- 229940087559 grape seed Drugs 0.000 claims abstract description 29
- 241001116389 Aloe Species 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000003826 tablet Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims abstract description 4
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 29
- 240000006891 Artemisia vulgaris Species 0.000 claims description 29
- 239000002537 cosmetic Substances 0.000 claims description 18
- 235000013376 functional food Nutrition 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 16
- 239000012676 herbal extract Substances 0.000 claims description 14
- 244000144927 Aloe barbadensis Species 0.000 claims description 13
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000037394 skin elasticity Effects 0.000 abstract description 6
- 230000002087 whitening effect Effects 0.000 abstract description 6
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 5
- 235000013402 health food Nutrition 0.000 abstract description 5
- 230000003020 moisturizing effect Effects 0.000 abstract description 5
- 235000017519 Artemisia princeps Nutrition 0.000 abstract 1
- 244000065027 Artemisia princeps Species 0.000 abstract 1
- 238000002835 absorbance Methods 0.000 description 31
- 230000002401 inhibitory effect Effects 0.000 description 24
- 239000000523 sample Substances 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 24
- 235000013305 food Nutrition 0.000 description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 150000003254 radicals Chemical class 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000032683 aging Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 102000016387 Pancreatic elastase Human genes 0.000 description 10
- 108010067372 Pancreatic elastase Proteins 0.000 description 10
- 102000003425 Tyrosinase Human genes 0.000 description 10
- 108060008724 Tyrosinase Proteins 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- -1 lipid peroxide Chemical class 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229930003427 Vitamin E Natural products 0.000 description 8
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 8
- 235000013734 beta-carotene Nutrition 0.000 description 8
- 239000011648 beta-carotene Substances 0.000 description 8
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 8
- 229960002747 betacarotene Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229950001002 cianidanol Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000013616 tea Nutrition 0.000 description 8
- 235000019165 vitamin E Nutrition 0.000 description 8
- 239000011709 vitamin E Substances 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 8
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 7
- 235000013793 astaxanthin Nutrition 0.000 description 7
- 229940022405 astaxanthin Drugs 0.000 description 7
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 7
- 239000001168 astaxanthin Substances 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000002292 Radical scavenging effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000003796 beauty Effects 0.000 description 5
- 235000002532 grape seed extract Nutrition 0.000 description 5
- 229940087603 grape seed extract Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 239000001717 vitis vinifera seed extract Substances 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 3
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
- 229940041476 lactose 100 mg Drugs 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 240000003553 Leptospermum scoparium Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002849 elastaseinhibitory effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000021021 grapes Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000021995 interleukin-8 production Effects 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- SUBFIBLJQMMKBK-UHFFFAOYSA-K iron(3+);trithiocyanate Chemical compound [Fe+3].[S-]C#N.[S-]C#N.[S-]C#N SUBFIBLJQMMKBK-UHFFFAOYSA-K 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KJHJAABRDASKAF-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione Chemical compound OC1=NC(O)=C2N=CNC2=N1.O=C1NC(=O)NC2=C1NC=N2 KJHJAABRDASKAF-UHFFFAOYSA-N 0.000 description 1
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003107 Artemisia maritima Nutrition 0.000 description 1
- 240000008118 Artemisia maritima Species 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- 244000231729 Astrocaryum tucuma Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000000630 Hedysarum occidentale Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- KQCHEWVHXSAJIA-UHFFFAOYSA-N Isoridentin Natural products C1CC(=C)C(O)CC(O)C(C)=CC2OC(=O)C(=C)C21 KQCHEWVHXSAJIA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001307210 Pene Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 244000236580 Psidium pyriferum Species 0.000 description 1
- 235000013929 Psidium pyriferum Nutrition 0.000 description 1
- SVCNNZDUGWLODJ-UHFFFAOYSA-N Riddelline Natural products O1C(=O)C(=CC)CC(=C)C(O)(CO)C(=O)OCC2=CCN3C2C1CC3 SVCNNZDUGWLODJ-UHFFFAOYSA-N 0.000 description 1
- KQCHEWVHXSAJIA-RNFGUGDUSA-N Ridentin Chemical compound C1CC(=C)[C@H](O)C[C@H](O)C(/C)=C/[C@H]2OC(=O)C(=C)[C@@H]21 KQCHEWVHXSAJIA-RNFGUGDUSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006388 chemical passivation reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000003502 gasoline Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LBAVIXQTLKRIGP-UHFFFAOYSA-N methyl dec-2-en-4,6,8-triynoate Chemical compound COC(=O)C=CC#CC#CC#CC LBAVIXQTLKRIGP-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940109529 pomegranate extract Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229930002161 purine alkaloid Natural products 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 피부노화 예방 및 미용 효과를 가지는 식품 조성물에 관한 것으로, 더욱 상세하게는 구아바 잎, 녹차, 쑥, 알로에 베라 및 포도씨로 이루어지는 군에서 선택된 1종 이상의 복합생약 혼합 추출물을 유효성분으로 함유하여, 피부 세포 증식을 통한 세포활성 효과로 피부탄력, 보습, 주름방지 및 미백 효능이 우수하면서, 부작용이 없어 인체에 안정하므로 피부 노화 예방 및 피부미용 효과가 우수한 식품 조성물에 관한 것이다. The present invention relates to a food composition having a skin aging prevention and cosmetic effect, and more particularly, containing as an active ingredient at least one compound herbal mixed extract selected from the group consisting of guava leaf, green tea, mugwort, aloe vera and grape seed. It is a food composition having excellent skin elasticity, moisturizing, anti-wrinkle and whitening effect through skin cell proliferation, while having no side effects and stable to the human body, thus preventing skin aging and skin beauty.
최근 생활수준이 향상됨에 따라 현대인들은 건강한 신체를 유지하는 것에 더하여 건강한 피부를 유지하는 데에도 많은 관심을 기울이고 있다. 따라서 피부미용 증진과 피부노화 방지에 대한 관심이 높아지고 있다.With the recent increase in living standards, modern people are paying more attention to maintaining healthy skin in addition to maintaining a healthy body. Therefore, interest in enhancing skin beauty and preventing skin aging is increasing.
인체의 가장 큰 기관으로서 전체 인체 부피의 약 16%를 차지하고 있는 피부 는 외부환경과 직접 접해 있으면서, 인체 안으로 침입하려는 치명적인 많은 유해인자, 예를 들면, 온도, 습도 및 자외선 등으로부터 인체를 보호하는 중요한 보호막 역할을 담당한다. 그러나, 나이가 들어감에 따라 각종 오염물질, 강한 자외선, 스트레스 및 영양결핍 등으로 인해 피부 세포들이 손상을 입게 되고, 세포 증식이 제대로 이루어지지 않게 되어 피부에 주름, 탄력 손실 및 각질화 등이 발생한다.As the largest organ of the human body, which occupies about 16% of the total body volume, the skin is in direct contact with the external environment and is important to protect the body from many deadly harmful factors such as temperature, humidity, and ultraviolet radiation. Act as a shield. However, as they age, skin cells are damaged due to various contaminants, strong ultraviolet rays, stress, and malnutrition, and cell proliferation is not performed properly, resulting in wrinkles, loss of elasticity, and keratinization.
피부 노화는 크게 자연 노화 (혹은 내인성 노화)와 외적 노화로 구분되며 (Doris EB, Cosmet. Toiletries, 1996, 111, 31), 자연 노화 (내인성 노화)는 유전적인 요소에 영향을 받기 때문에 인위적인 조절이 어려운 반면 외적노화는 환경적인 요소에 영향을 받기 때문에 인위적인 조절이 비교적 용이하다. 대표적인 외적 노화 인자로는 자외선, 활성 산소종(reactive oxygen species) 및 스트레스 등으로, 가장 두드러진 외적인 노화 현상은 주름 형성이며(Daniell HW, Ann. Intern. Med., 1971, 75(6), 873; Grove GL 등, J. Am. Acad. Dermatol., 1989, 21(3), 631; Griffiths CE 등, Arch. Dermatol., 1992, 128, 347) 그 결과 피부 탄력이 현저히 감소하게 된다.Skin aging is largely divided into natural aging (or endogenous aging) and external aging (Doris EB, Cosmet. Toiletries, 1996, 111, 31), and natural aging (endogenous aging) is influenced by genetic factors, so artificial regulation On the other hand, external aging is relatively easy to artificially adjust because of environmental factors. Representative external aging factors include ultraviolet light, reactive oxygen species and stress, and the most prominent external aging phenomenon is wrinkle formation (Daniell HW, Ann. Intern. Med., 1971, 75 (6), 873; Grove GL et al., J. Am. Acad. Dermatol., 1989, 21 (3), 631; Griffiths CE et al., Arch. Dermatol., 1992, 128, 347). As a result, skin elasticity is significantly reduced.
피부의 노화 기작을 규명하기 위한 여러 연구들이 진행되어 여러 가지 피부 노화의 원인들이 밝혀졌다. 피부가 온도의 변화, 습도의 저하 또는 바람 등에 의해 건조하게 되면 외부에 대한 방어벽으로서의 피부 생리 활성이 저하되어 노화가 촉진된다. 또한, 유해 활성 산소종 또는 자유 라디칼에 피부가 노출되면 체내의 산화 작용에 의해 과산화 지질이 생성되고 피부를 구성하는 여러 단백질들의 변형을 유발하게 된다. 자외선에 의해 야기되는 광노화 메커니즘 중의 하나는 자유 라디칼 경로를 경유하는 것이다 (Harman D,J. Gerontol., 1956, 11(3), 298). 자유 라디칼들은 피부 콜라겐 등의 결합 조직 형성 파괴, 세포막 기능저해, DNA 변이 촉진, 단백질 작용 변형, 세포간 에너지 전이, 신진 대사와 관련된 분자들의 변형 등을 유발하는 것으로 알려져 있다 (Lavker RM 및 Kligman AM, J. Invest. Dermatol., 1988, 90, 325). 노화에 자유 라디칼이 관여한다는 사실은 자유 라디칼을 불활성화시키는 항산화제 또는 여러가지 화학적 소거제들을 사용하여 노화 과정을 지연시킬 수 있다는 것을 의미한다. Various studies have been conducted to investigate the mechanism of aging of the skin, revealing various causes of skin aging. When the skin is dried by a change in temperature, a decrease in humidity or wind, the skin physiological activity as a protective barrier against the outside is lowered to promote aging. In addition, exposure of the skin to harmful reactive oxygen species or free radicals causes oxidative action in the body to produce lipid peroxide and cause modification of the various proteins that make up the skin. One of the photoaging mechanisms caused by ultraviolet light is via free radical pathways (Harman D, J. Gerontol., 1956, 11 (3), 298). Free radicals are known to cause breakdown of connective tissue formation, such as cutaneous collagen, cell membrane dysfunction, facilitating DNA mutations, altering protein function, intercellular energy transfer, and metabolism related molecules (Lavker RM and Kligman AM, J. Invest.Drmatol., 1988, 90, 325). The fact that free radicals are involved in aging means that antioxidants or various chemical scavengers that inactivate the free radicals can be used to delay the aging process.
또한, 피부의 진피조직 속에는 콜라겐(collagen)과 피부의 탄력성에 관련된 엘라스틴 (elastine)이 그물망 구조를 형성하고 있는데, 이러한 그물망 구조가 깨어지면서 즉, 엘라스틴이 엘라스틴 분해효소(elastase)에 의해 분해되어 피부가 처지고 주름이 생기므로 내인성 피부노화가 발생한다. 그러므로, 피부노화의 주원인 중의 하나인 엘라스틴 분해효소(elastase)의 활성을 저하시킴으로써 피부노화를 억제할 수 있다.In addition, collagen and elastine related to the elasticity of the skin form a network structure in the dermal tissue of the skin. As the network structure is broken, that is, elastin is decomposed by elastin degrading enzyme (elastase). And wrinkling causes endogenous skin aging. Therefore, skin aging can be suppressed by lowering the activity of elastinase, one of the main causes of skin aging.
종래에는 피부노화 방지를 위하여 거의 피부 표면에 바르는 화장품에 의존해왔다. 대한민국 공개특허공보 제2001-65755호에는 피부세포 증식, 콜라겐섬유 합성 촉진 등 피부 주름개선 및 탄력증진 효과가 있는 베타-1,3-글루칸과 인삼사포닌 함유 외용제 조성물이 개시되어 있으며, 대한민국 특허등록 제423,521호에는 주름개선효과, 콜라겐합성촉진효과, 광접촉에 의한 손상피부회복효과, 보습효과를 나타내는 인삼다당체를 함유한 화장품 조성물이 개시되어 있다. 그러나 직접 피부 표면에 적용되는 외용제 및 화장품은 진피층까지 흡수되지 못하고, 표피에만 작용하므로 피부노화 방지효과가 일시적이고, 그 부작용으로 피부가 손상되기도 하는 문제점이 있다. 또한 체내에 있는 활성산소를 제거하지 못하여, 활성산소에 의한 노화작용을 막기에는 한계가 있었다. Conventionally, it has been relied on cosmetics that are almost applied to the skin surface to prevent skin aging. Korean Unexamined Patent Publication No. 2001-65755 discloses a beta-1,3-glucan and ginseng saponin-containing external preparation composition having skin wrinkle improvement and elasticity enhancing effects such as skin cell proliferation and collagen fiber synthesis. No. 423,521 discloses a cosmetic composition containing ginseng polysaccharides that exhibits anti-wrinkle effect, collagen synthesis promoting effect, damaged skin recovery effect by optical contact, and moisturizing effect. However, the external preparations and cosmetics applied directly to the skin surface are not absorbed up to the dermal layer, and act only on the epidermis, so that the skin aging prevention effect is temporary, and there is a problem that the skin is damaged as a side effect. In addition, the active oxygen in the body can not be removed, there was a limit to prevent the aging action by the active oxygen.
또한, 화학물질로 이루어진 미용 식품 조성물들은 그 부작용이 있어 많은 폐단을 초래하는 이유로, 천연물질 등을 이용하여 장기간 사용 시에도 안정성이 높은 피부노화 방지 및 개선 물질을 개발하의 필요성이 절실히 요구되고 있는 실정이다.In addition, the cosmetic food compositions made of chemicals have a lot of side effects that cause a lot of discontinuation, the situation is urgently required to develop a highly stable skin aging prevention and improvement material even when using for a long time using natural materials. to be.
본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위하여 창출된 것으로서, 본 발명의 목적은 천연물 유래의 피부노화 예방 및 개선효능을 가진 식품연구에 주력한 결과, 구아바잎, 녹차, 쑥, 알로에 및 포도씨의 복합생약 추출물을 함유하는 조성물이 피부미용과 건강에 유용하고 특히 피부 세포 증식을 통한 세포활성 효과로 피부탄력, 보습, 주름방지 및 미백 효능이 우수하면서, 부작용이 없어 인체에 안정하기 때문에 우수한 피부노화 예방 및 개선 효과를 가지는 기능성 식품 제제로의 적용이 가능한 피부노화 예방 및 미용 효과를 지니는 복합생약 조성물을 제공하는데 있다.The present invention was created in order to solve the problems of the prior art as described above, the object of the present invention is a result of focusing on the research of foods with the prevention and improvement of skin aging derived from natural products, guava leaf, green tea, mugwort, aloe and The composition containing the extract of the complex herbal extract of grape seed is useful for skin beauty and health, and it is excellent for skin elasticity, moisturizing, anti-wrinkle and whitening effect due to the cell activity effect through skin cell proliferation, and is stable to human body because of no side effect. It is to provide a complex herbal composition having a skin aging prevention and cosmetic effect that can be applied to a functional food formulation having a skin aging prevention and improvement effect.
상기의 목적을 실현하기 위한 본 발명의 일 실시예에 따른 피부노화 예방 및 미용 효과를 지니는 복합생약 조성물은 구아바잎, 녹차, 쑥, 알로에 및 포도씨로 구성되는 군으로부터 선택된 하나 이상의 생약 추출물을 유효성분으로 함유하는 것을 그 특징으로 한다.Composite herbal composition having a skin aging prevention and cosmetic effect according to an embodiment of the present invention for achieving the above object is an active ingredient extract of at least one herbal extract selected from the group consisting of guava leaf, green tea, mugwort, aloe and grape seed It is characterized by containing it.
본 발명의 바람직한 한 특징으로서, 상기 추출물은 구아바잎, 녹차, 쑥, 알로에 베라 및 포도씨의 복합생약 추출물 중 적어도 어느 하나 또는 하나 이상을 포함하는 것에 있다.As a preferred feature of the present invention, the extract is to include at least one or more than one of the herbal extract of guava leaf, green tea, mugwort, aloe vera and grape seed.
본 발명의 바람직한 다른 특징으로서, 상기 복합생약 추출물의 구성배합비가 구아바잎: 녹차: 쑥: 알로에베라: 포도씨(1~3: 1~3 : 1~2: 1~2: 1~2)의 중량비(w/w)인 것에 있다.As another preferred feature of the present invention, the composition ratio of the complex herbal extract is guava leaf: green tea: mugwort: aloe vera: grape seed (1-3: 1-3: 1-2: 1-2: 1-2) It is in (w / w).
상기의 목적을 실현하기 위한 본 발명의 일 실시예에 따른 피부노화 예방 및 개선용 건강 기능 식품은 구아바잎, 녹차, 쑥, 알로에 베라 및 포도씨로 구성되는 군으로부터 선택된 하나 이상의 생약 추출물을 유효성분으로 포함하는 것을 그 특징으로 한다.Health functional food for preventing and improving skin aging according to an embodiment of the present invention for achieving the above object is at least one herbal extract selected from the group consisting of guava leaf, green tea, mugwort, aloe vera and grape seed as an active ingredient It is characterized by including.
본 발명의 바람직한 한 특징으로서, 상기 추출물은 구아바잎, 녹차, 쑥, 알로에 베라 및 포도씨의 복합생약 추출물 중 적어도 어느 하나 또는 하나 이상을 포함하는 것에 있다.As a preferred feature of the present invention, the extract is to include at least one or more than one of the herbal extract of guava leaf, green tea, mugwort, aloe vera and grape seed.
본 발명의 바람직한 다른 특징으로서, 상기 복합생약 구성배합비가 구아바잎: 녹차: 쑥: 알로에 베라: 포도씨(1~3: 1~3 : 1~2: 1~2: 1~2) 중량비(w/w)인 것에 있다.As another preferable feature of the present invention, the compound herbal composition ratio is guava leaf: green tea: mugwort: aloe vera: grape seed (1-3: 1-3: 1-2: 1-2: 1-2) weight ratio (w / is in w).
본 발명의 바람직한 또 다른 특징으로서, 정제·캡슐제· 환제·액제 중 어느 하나인 것에 있다.Another preferable feature of the present invention is any one of tablets, capsules, pills, and liquids.
본 발명의 특징 및 이점들은 첨부도면에 의거한 다음의 상세한 설명으로 더욱 명백해질 것이다. 이에 앞서 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이고 사전적인 의미로 해석되어서는 아니 되며, 발명자가 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합되는 의미와 개념으로 해석되어야만 한다.The features and advantages of the present invention will become more apparent from the following detailed description based on the accompanying drawings. Prior to this, the terms or words used in this specification and claims are not to be interpreted in a conventional and dictionary sense, and the inventors may appropriately define the concept of terms in order to best explain their invention in the best way possible. It should be interpreted as meaning and concept corresponding to the technical idea of the present invention based on the principle that the present invention.
본 발명에 따른 피부노화 예방 및 미용 효과를 지니는 복합생약 조성물은 구아바잎, 녹차, 쑥, 알로에 및 포도씨의 수용성 추출물로 이루어져 우수한 피부노화 예방 개선 효과를 지니므로 기능성 조성물 및 건강기능 식품으로 사용될 수 있다.The complex herbal composition having the skin aging prevention and cosmetic effect according to the present invention is composed of water-soluble extracts of guava leaf, green tea, mugwort, aloe and grape seed, and thus can be used as a functional composition and health functional food because it has excellent skin aging prevention and improvement effect. .
이하, 첨부된 도면을 참조하여 본 발명에 따른 피부노화 예방 및 미용 효과를 지니는 복합생약 조성물을 설명하면 다음과 같다. Hereinafter, with reference to the accompanying drawings illustrating a composite herbal composition having a skin aging prevention and cosmetic effects according to the present invention.
먼저, 도면들 중 동일한 구성요소 또는 부품들은 가능한 동일한 참조부호로 나타내고 있음을 유의하여야 한다. 본 발명을 설명함에 있어 관련된 공지의 기능 혹은 구성에 대한 구체적인 설명은 본 발명의 요지를 모호하지 않게 하기 위하여 생략한다.First, it should be noted that like elements or parts in the drawings are denoted by the same reference numerals as much as possible. In the following description of the present invention, detailed descriptions of well-known functions or configurations will be omitted in order not to obscure the subject matter of the present invention.
도 1은 본 발명의 실시예 2의 기능성 조성물의 티로시나제 저해활성 결과를 나타낸 도면이고, 도 2는 본 발명의 실시예 2의기능성 조성물을 섭취시 나타나는 컨디션 및 체질 변화를 나타낸 도면이다. 1 is a view showing the results of tyrosinase inhibitory activity of the functional composition of Example 2 of the present invention, Figure 2 is a view showing the changes in condition and constitution when ingesting the functional composition of Example 2 of the present invention.
그리고, 도 3은 본 발명의 실시예 2의기능성 조성물을 섭취시 나타나는 피부상태의 변화를 나타낸 도면이다.And, Figure 3 is a view showing a change in skin condition appearing when ingesting the functional composition of Example 2 of the present invention.
본 발명은 구아바잎, 녹차, 쑥, 알로에 및 포도씨로 구성되는 군으로부터 선택된 하나 이상의 생약 추출물을 함유하는 피부 노화 예방 및 미용 효과를 갖는 기능성 식품 조성물을 제공한다. The present invention provides a functional food composition having skin aging prevention and cosmetic effects containing at least one herbal extract selected from the group consisting of guava leaf, green tea, mugwort, aloe and grape seed.
또한, 본 발명의 기능성 식품 조성물은 상기 성분을 유효성분으로 하고, 여기에 보조성분으로 피부미용 증진 및 피부노화 방지효과를 높이기 위하여 콜라겐 펩티드, 대두추출물, 식이섬유, 석류추출물, 비타민 C, 비타민 B2, 비타민 B6 등을 포함할 수 있으며, 식품 제조 시에 통상적으로 첨가되는 성분을 더 포함할 수 있다. 식품 제조 시에 통상적으로 첨가되는 성분은 여러가지 영양제(비타민, 아미노산, 항산화제 등), pH 조절제(구연산, 구연산소다), 감미제(액상과당, 에리스리톨, 파라치노스, 저당 등), 합성 풍미제 등의 풍미제, 착색제, 부형제(유당, 포도당, 전분, 락츄로스 등), 안정화제, 활택제(스테아린산 마그네슘), 유지류(소맥배아유, 올리브유, 밀납, 왁스, 토코페롤 등)을 의미한다. 이러한 성분은 독립적으로 또는 조합하여 사용될 수 있다.In addition, the functional food composition of the present invention as the active ingredient, the collagen peptide, soybean extract, dietary fiber, pomegranate extract, vitamin C, vitamin B2 in order to enhance skin beauty and prevent skin aging as an auxiliary ingredient It may include vitamin B6 and the like, and may further include ingredients that are commonly added during food production. Commonly added ingredients in food manufacturing include various nutrients (vitamins, amino acids, antioxidants, etc.), pH adjusters (citric acid, sodium citrate), sweeteners (liquid fructose, erythritol, parachinose, mortgage, etc.), synthetic flavors, etc. Flavors, colorants, excipients (lactose, glucose, starch, lacchurose, etc.), stabilizers, glidants (magnesium stearate), fats and oils (wheat germ oil, olive oil, beeswax, wax, tocopherol, etc.). These components can be used independently or in combination.
한편 본 발명의 기능성 식품 조성물은 통상적으로 알려진 방법에 따라 다양한 형태의 식품으로 제조될 수 있고, 환제, 음료, 차, 과립, 정제, 경질캅셀제, 연질캅셀제 등 여러 제형의 식품으로서 제조가 가능하다.Meanwhile, the functional food composition of the present invention may be prepared in various forms of food according to a conventionally known method, and may be prepared as food of various formulations such as pills, beverages, tea, granules, tablets, hard capsules, and soft capsules.
구체적으로, 본 발명의 상기 조성물은 구아바잎 수용성 추출물 10-40 중량 %, 녹차 수용성 추출물 10-40 중량 %, 쑥 수용성 추출물 20-70 중량 % 및 알로에 수용성 추출물 10-40 중량 %, 및 포도씨 수용성 추출물 10-50 중량 %의 조성비를 갖는 식품 추출물로 구성되는 것이다. Specifically, the composition of the present invention is a guava leaf water-soluble extract 10-40% by weight, green tea water-soluble extract 10-40% by weight, mugwort water-soluble extract 20-70% by weight and aloe water-soluble extract 10-40% by weight, and grape seed water-soluble extract It consists of a food extract having a composition ratio of 10-50% by weight.
본 발명은 구아바잎, 녹차, 쑥, 알로에 및 포도씨를 80 내지 110 ℃에서 1 내지 5시간 열수 추출하여 고형분이 10 내지 40 %가 되도록 농축한 후 건조한 건조 농축물을 배합하여 이루어진 피부노화 예방 및 미용 효과를 지니는 기능성 식품 제제 및 화장품 제제를 제공한다.The present invention extracts guava leaf, green tea, mugwort, aloe and grape seeds from 80 to 110 ℃ hot water for 1 to 5 hours, concentrated to 10 to 40% solids, and then mixed with dry dry concentrate to prevent skin aging and beauty Functional food formulations and cosmetic formulations are provided.
또한, 본 발명은 구아바잎, 녹차, 쑥, 알로에 및 포도씨로 이루어진 군으로부터 선택된 하나 이상의 복합 생약 추출물을 함유하는 피부노화 예방 및 미용 효과를 지니는 식품첨가제를 제공한다.The present invention also provides a food additive having a skin aging prevention and cosmetic effect containing one or more complex herbal extracts selected from the group consisting of guava leaf, green tea, mugwort, aloe and grape seed.
상기 식품첨가제는 식품 총 중량에 대하여, 0.01 중량 % 내지 10 중량 %로 포함될 수 있다.The food additive may be included in an amount of 0.01 wt% to 10 wt% based on the total weight of the food.
한편, 본 발명에 사용되는 추출물을 구성하는 요소 중, 구아바(psidium guajava L.)는 도금양과(Myrtaceae과) 피지디움(Psidium)속의 식물로 열대아메리카가 원산지로 키가 작은 나무이며, 잎, 나무껍질, 열매 등을 건강식 및 약용으로 이용할 수 있다. 번식력이 강하여 재배시, 농약의 사용없이 재배가 가능하고, 일반적으로 이질, 설사에 효과가 있는 것으로 알려져 있다. 그 성분으로는 탄닌의 함량이 높고, 탄닌은 정장, 위장 기능의 강화, 노화 방지, 항암 효과가 있는 것으로 알려져 있다. 그 외 성분으로는 지방유, 정유, 휘발유, 인슐린 성분, 비타민 B군, 비타민 C, 마그네슘, 칼륨 등 비타민과 미네랄이 함유되어 있고, 제균, 수렴, 지사, 소염, 지혈, 히스타민 유리억제, 혈당저하, 항산화, 혈관 투과성 억제 등의 약리 활성이 알려져 있다(안덕균 저, 한국본초도감, 교학사, 1999).On the other hand, among the elements constituting the extract used in the present invention, guadium ( psidium guajava L.) is a genus of the genus Myrtaceae (Psidium) genus (Psidium) is a short tree originated in tropical America, leaves, trees Peel, fruit, etc. can be used for health food and medicinal. It is known that it has strong fertility and can be cultivated without using pesticides, and is generally effective for dysentery and diarrhea. Its content is high in tannins, and tannins are known to have a formal, gastrointestinal function, anti-aging and anticancer effects. Other ingredients include fatty oils, essential oils, gasoline, insulin, vitamin B group, vitamin C, magnesium, potassium and other vitamins and minerals, and antibacterial, astringent, branch, anti-inflammatory, hemostatic, histamine free, hypoglycemic, Pharmacological activities, such as antioxidant and vascular permeability inhibition, are known (Anduk Kyun, Korea Herb Book, Kyohaksa, 1999).
녹차는 차나무(Camellia sinensis)의 잎을 말린 것으로서 차나무과(Theaceae)에 속하며, 차나무의 어리고 연한 잎은 퓨린계 알칼로이드와 카페인을 주로 함유하고 있으며, 그 함유량은 1 내지 5 % 이다. 이 밖에 미량이기는 하지만, 테오브로민(theobromine), 테오필린(theophylline), 잔틴(xanthine)이 함유되어 있다. 차 잎의 탄닌은 주로 갈로일-l-에피갈로카테콜(galloyl-l-epigallocatechol)이며, 이는 카페인과 함께 함유되어 있다. 차 잎의 약리작용은 주로 잔틴 유도체(카페인 및 테오필린)에 의하여 생기고, 그 밖에 대량의 탄닌산을 함유하므로 항균 및 비타민 P와 같은 작용을 한다. 약리작용으로는 중추신경계를 흥분시켜 정신기능을 촉진하고, 사고력을 높이며 피로를 없애며 관상혈관을 확장하고, 이뇨작용이 있다(정 보섭 및 신 민교, 향약대사전, pp403-405, 영림사, 1998). 차나무의 어린 잎은 가공 방법에 따라서 향미가 다른 여러 종류의 차를 제조할 수 있는데, 예로서, 후발효, 발효, 반발효, 불발효 등의 제조공법에 따라 각각 보이차, 홍차, 우롱차, 철광음, 포종차, 녹차 등을 제조할 수 있다. Green tea is a dried leaf of Camellia sinensis and belongs to Theaceae. The young and soft leaves of tea tree mainly contain purine alkaloid and caffeine, and its content is 1 to 5%. In addition to the trace amount, theobromine (theobromine), theophylline (theophylline) and xanthine (xanthine) is contained. Tannin in tea leaves is mainly galloyl - l - is going to epi catechol (galloyl- l -epigallocatechol), which is contained together with caffeine. The pharmacological action of tea leaves is mainly caused by xanthine derivatives (caffeine and theophylline), and also contains a large amount of tannic acid, thus acting as antibacterial and vitamin P. Pharmacological action is to excite the central nervous system, promote mental function, increase thinking ability, eliminate fatigue, expand coronary blood vessels, and diuretic (Jung Bo-seop and Shin Min-kyo, Ph.D., pp403-405, Younglimsa, 1998) . The young leaves of the tea tree can produce various kinds of teas with different flavors depending on the processing method. For example, the tea leaves, black tea, oolong tea, Iron ore, cannon tea, green tea, etc. can be manufactured.
약 쑥(애엽, A. princeps var. orientalis (PAMPAN.) HARA)은 다년생 초본으로 황해쑥 및 동속 근록식물의 잎을 말린 것이다. 황해쑥은 정유를 함유하며 정유 중 가장 함유량이 많은 성분은 시네올(cineole)로 25~30 %를 차지한다. 이 밖에 β-카로필렌(β-carophyllene), 리날로올(linalool), 캠퍼(camphor), 보르네올(borneol) 등이 함유되어 있다. 잎은 테트라코사놀(tetracosanol), β-시토스테롤(β-sitosterol), l-쉐불라키톨(l-chebulachitol), l-이노시톨(l-inositol)을 함유한다. 뿌리 및 줄기는 이눌린(inulin)과 비슷한 다당 아르테모즈(artemose)를 함유한다. 뿌리는 다종의 폴린(polyin) 화합물을 함유하며 이것에는 헵타덱-1, 7, 9,-트리엔-11, 13, 15-트린(heptadec-1, 7, 9,-trien-11, 13, 15-triyne), 테트라데카-8, 10, 12,-트린-6-엔-3-원(tetradeca-8, 10, 12,-trine-6-ene-3-one) 및 메틸 2-데칸-4, 6, 8-트리네이트(methyl 2-decen-4, 6, 8-triynate)가 있다. 또 작은 가지는 옥시톡신(oxytoxin)과 같은 작용을 하는 물질을 포함하고 있다. 또한 애속의 수많은 식물 속에서는 세스퀘테르펜 락톤(sesquiterpene lactone)의 리덴틴(ridentin)이 포함되고 있다. 또한 기혈을 다스리고 한습을 몰아내며 온경, 지혈, 안태의 효능이 있다. 복부의 냉증에 의한 통증, 설사전근, 만성하리, 토혈, 비출혈, 하혈, 월경불순, 붕루, 대하, 태동불안, 옹양, 개선을 치료한다(정 보섭 및 신 민교 저, 향약대사전, 영림사, pp1014~1016, 1998).The wormwood ( A. princeps var . Orientalis (PAMPAN.) HARA) is a perennial herb that is dried on the leaves of Yellow Sea Mugwort and its equivalents. Yellow sea wormwood contains essential oils and the highest content of essential oils is cineole, accounting for 25-30%. In addition, β-carophyllene (β-carophyllene), linalool (linalool), camphor (camphor), borneol (borneol) and the like is contained. Leaves are tetra Kosa play (tetracosanol), β- sitosterol (β-sitosterol), l - contains inositol (l -inositol) - swebul Rocky Tall (l -chebulachitol), l. Roots and stems contain polysaccharide artemis similar to inulin. The root contains a variety of polyin compounds, including heptadec-1, 7, 9, -triene-11, 13, 15-trine (heptadec-1, 7, 9, -trien-11, 13, 15-triyne), tetradeca-8, 10, 12, -tri-6-6-ene-3-one and methyl 2-decane- 4, 6, 8-triynate (methyl 2-decen-4, 6, 8-triynate). Small branches also contain substances that act like oxytoxins. In addition, numerous plants in the genus contain sedentin pene lactone (ridentin). In addition, it governs blood donation, drives out humidity and has the effects of warmth, haemostasis, and safety. Treatment of cold pain in the abdomen, diarrhea, muscle diarrhea, chronic bleeding, hemorrhage, nasal bleeding, bleeding, dysmenorrhea, abortion, crayfish, infertility, ongyang, improvement pp 1014-1016, 1998).
알로에 베라(Aloe vera, Aloe barbadensis Miller)는 알로에 껍질을 벗겨내고 젤리질만을 사용한 것으로 이 젤리질에는 보습력이 뛰어나며 인체의 면역 증강 효과 및 상처 치유 작용이 있는 다당류(Polysaccharids)와 인체에 혈당 강하 작용을 하는 당단백(Glycoprotein) 등의 유효성분이 다량 함유되어 있다 (안 덕균, 한국 본초도감, pp280, 교학사, 2000: 김 창민, 원색 한약도감, pp306, 아카데미서적, 2001).Aloe vera (Aloe barbadensis Miller) is a peeled aloe and using only jelly, which is a highly moisturizing polysaccharide (Polysaccharids) that enhances the body's immunity and wound healing, and glycoprotein that lowers blood sugar. (Glycoprotein) contains a large amount of active ingredients (Duk-kyun Ahn, Korean Herbal Painting, pp280, Kyohaksa, 2000: Changmin Kim, Primary Color Herbal Painting, pp306, Academy Book, 2001).
포도씨는 이시진(李時珍)의 본초강목(本草綱目)에서 포도는 힘줄과 뼈의 습비를 다스리고 기를 높여 힘을 세게 해주며, 의지를 굳게 해주고 건강하게 해주며, 또한 허기를 참을 수 있는 인내력을 주며 감기에 강하게 하는 등의 효과가 있으므로, 포도를 오래 먹으면 몸이 가벼워지고 늙지 않아 오래 살 수 있다고 하였다. 이러한 포도씨의 추출물은 생리학적 효능이 우수하여 기능성 식품 또는 치료제 등으로 개발하려는 시도가 활발히 이루어지고 있는 바, 한국 공개특허 제 98-51189호에서 티로시나제 저해제로서의 포도씨 추출물, 한국 등록특허 제 00-18117호에서 포도씨 추출 천연 항충치제, 한국 공개특허 제 01-12238호에서 포도씨 추출물로 코팅된 쌀 등의 상기 포도씨 추출물을 함유하는 기능성 식품을 개시한 바 있으며, 한국공개특허 제 00-63265호에서 항산화 물질이 함유된 포도씨 기름과 그 제조방법, 한국공개특허 제 01-04553호에서 항산화 효과가 향상된 포도제품의 제조방법, 한국공 개특허 제 99-28877호에서 프로시아니딘을 유효성분으로 하는 약효제 등 포도씨추출물의 주성분인 프로안토시아니딘(proanthocyanidin)의 항산화 효능에 대한 용도에 관하여 개시한 바 있다. Grape seed in the main sichuan of Ishijin (珍 草 綱), the grapes control the strength and tenderness of the tendons and bones to strengthen the strength, strengthen the will, keep healthy, and also endure hunger and endure cold It is said that it is effective in strengthening, so if you eat grapes for a long time, your body will become lighter and not old. Since the extract of grape seed has excellent physiological efficacy, an attempt has been actively made to develop it as a functional food or a therapeutic agent. In Korean Patent Publication No. 98-51189, the grape seed extract as a tyrosinase inhibitor, Korean Patent No. 00-18117 Grape seed extract from natural anti-cavities, Korean Patent Publication No. 01-12238 has disclosed a functional food containing the grape seed extract, such as rice coated with grape seed extract, antioxidants in Korea Patent Publication No. 00-63265 Grape seed oil containing the same and a method for manufacturing the same, a method for producing grape products having improved antioxidant effect in Korean Patent Publication No. 01-04553, a grape seed extract such as a medicinal agent using prosanidine as an active ingredient in Korean Patent Publication No. 99-28877 The use of the antioxidant component of proanthocyanidin, which is a major component of the present invention, has been disclosed.
이하, 본 발명에 따른 피부노화 예방 및 미용 효과를 지니는 복합생약 조성물 그리고 피부노화 예방 및 개선용 건강 기능 식품의 제조방법 및 그 실시예를 상세히 설명한다. Hereinafter, a method of preparing a composite herbal composition having a skin aging prevention and cosmetic effect and a health functional food for preventing and improving skin aging according to the present invention and an embodiment thereof will be described in detail.
본 발명에 사용된 구아바잎, 녹차, 쑥, 알로에 및 포도씨 각각의 추출물을 제조하기 위해서 구체적으로는, 구아바잎, 녹차, 쑥, 알로에 및 포도씨를 세척 후, 그늘에서 충분히 건조시키고 세절하거나 분쇄한 다음, 무게(㎏)의 약 1배 내지 30배의 물, 에탄올과 같은 저급 알콜 또는 이들의 혼합용매, 바람직하게는 물로 20 내지 120 ℃, 바람직하게는 100 내지 110 ℃ 추출온도에서 약 1시간 내지 2일, 바람직하게는 약 2시간 내지 12시간 동안, 1회 내지 10회, 바람직하게는 2회 내지 5회 반복적으로 열수추출, 초음파 추출, 환류냉각 추출 등의 추출방법, 더욱 바람직하게는 80 내지 110 ℃에서 1 내지 5시간 열수 추출 방법에 의하여 물, 저급 알콜 또는 이들의 혼합용매에 따른 가용추출물인 조추출물을 수득하여 여과하고, 감압농축 또는 진공 농축하여 추출농축액을 수득할 수 있으며, 부가적으로 동결 건조시켜 분말형태로 수득된다.To prepare extracts of guava leaf, green tea, mugwort, aloe and grape seed, used in the present invention, specifically, after washing guava leaf, green tea, mugwort, aloe and grape seed, they are sufficiently dried in the shade and then chopped or crushed. , About 1 to 30 times the weight (kg), lower alcohols such as ethanol, or a mixed solvent thereof, preferably water, 20 to 120 ° C., preferably 100 to 110 ° C. at an extraction temperature of about 1 hour to 2 One, preferably about 2 to 12 hours, 1 to 10 times, preferably 2 to 5 times repeatedly extraction method, such as hot water extraction, ultrasonic extraction, reflux cooling extraction, more preferably 80 to 110 The crude extract, which is a soluble extract according to water, lower alcohol, or a mixed solvent thereof, was filtered by hot water extraction at 1 ° C. for 5 hours, and concentrated under reduced pressure or concentrated in vacuo to extract the extract concentrate. It may deukhal and lyophilized additionally is obtained in powder form.
본 발명 조성물의 재료로서 사용되는 생약 식물들은 직접 제조하거나 시중에 서 구입하여 사용할 수도 있으며, 본 발명의 생약 식물들의 추출물은 20 내지 90 % 의 고농축액의 형태 또는 분말형태로 본 식품조성물에 사용될 수 있다.The herbal plants used as the material of the composition of the present invention may be prepared directly or purchased commercially, the extracts of the herbal plants of the present invention may be used in the food composition in the form of powder or powder of 20 to 90% high concentration. have.
본 발명의 기능성 식품 조성물은 건강을 위한 식품, 음료, 또는 음료첨가제로 사용할 수 있으며, 상기 기능성 조성물은 식품 총 중량에 대하여 0.01 % 내지 10 중량 %로 물에 혼합하여 피부노화 예방 및 개선을 목적으로 한 기능성 음료 또는 상기 조성 성분을 건조 분말화하여 충진한 연질 또는 경질 캡슐제, 정제, 과립, 드롭프스 및 티백 형태를 하는 기능성 식품 분야와 스킨, 크림, 로션 및 비누 형태를 하는 기능성 화장품 분야에 적용하는 것이 바람직하다.Functional food composition of the present invention can be used as a food, beverage, or beverage additives for health, the functional composition is mixed with water in 0.01% to 10% by weight relative to the total weight of food for the purpose of preventing and improving skin aging Applied in the field of functional foods in the form of soft or hard capsules, tablets, granules, drops and tea bags filled with dry powders of the functional beverages or functional ingredients and in the field of functional cosmetics in the form of skins, creams, lotions and soaps. It is preferable.
본 발명의 유효성분을 포함하는 조성물은 피부노화 예방 및 개선을 위한 식품 및 화장품 등에 다양하게 이용될 수 있다. 본 조성물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 캔디, 과자류, 차, 비타민 복합제, 건강기능 식품류 등이 있으며 화장품으로는 스킨, 크림, 로션 및 비누류 등이 있다. The composition containing the active ingredient of the present invention can be used in various foods and cosmetics for preventing and improving skin aging. Examples of the food to which the composition can be added include various foods, beverages, gums, candy, confectionery, tea, vitamin complexes, health functional foods, and the like, and cosmetics include skins, creams, lotions and soaps. have.
본 발명의 구아바잎, 녹차, 쑥, 알로에 및 포도씨의 수용성 추출물은 오랫동안 식품으로 사용되어 오던 것으로서 이로부터 추출된 본 발명의 추출물 역시 독성 및 부작용은 거의 없으므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있다. The water-soluble extracts of guava leaf, green tea, mugwort, aloe and grape seed of the present invention have been used for a long time as the extract of the present invention has little toxicity and side effects, so it can be used with confidence even for long-term use for prophylactic purposes. have.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예 및 실험예를 제시한다. 그러나 하기의 실시예 및 실험예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐 본 발명이 하기의 실시예 및 실험예에 한정되는 것은 아니다. Hereinafter, preferred examples and experimental examples are presented to help understand the present invention. However, the following Examples and Experimental Examples are provided only to more easily understand the present invention, and the present invention is not limited to the following Examples and Experimental Examples.
실시예 1. 필수 식물 추출물 제조예 Example 1 Preparation of Essential Plant Extracts
(주)농림생약(충남 아산시 배방면)에서 구입한 녹차, 쑥, 알로에, 포도씨 그리고 (주)진용네츄럴(경기도 수원시 팔달구)서 구입한 구아바를 각각 30 g씩을 물 600 mL에 넣고 110 ℃에서 3시간 열수 추출하여 이를 진공농축기(Buchi R-114, Buchi사, Switzerland)로 고형분이 30 %가 될 때까지 농축한 후, 그 농축물을 동결건조기(FD 5512, Ilsin사, Korea)로 동결 건조하여 구아바잎, 녹차, 쑥, 알로에 및 포도씨에서 각각 3.1, 2.5, 2.3, 2.8 및 1.0 g의 건조 분말을 제조하였다.30 g each of green tea, mugwort, aloe, grape seed, and guava purchased from Agriculture & Forestry Co., Ltd. (Baebang-myeon, Asan-si, Chungnam) and guava purchased from Jinyong Natural (Paldal-gu, Suwon-si, Gyeonggi-do) were put in 600 mL of water for 3 hours. Hot water is extracted and concentrated using a vacuum concentrator (Buchi R-114, Buchi, Switzerland) until the solid content reaches 30%, and the concentrate is freeze-dried with a freeze dryer (FD 5512, Ilsin, Korea) and guava. 3.1, 2.5, 2.3, 2.8 and 1.0 g of dry powder were prepared from leaves, green tea, mugwort, aloe and grape seed, respectively.
실시예 2. 기능성 조성물 제조예 Example 2 Preparation of Functional Composition
상기 실시예 1에서 제조된 구아바잎, 녹차, 쑥, 알로에 및 포도씨 수용성 추출물을 고형분 함량 % 기준으로 각각 25%, 15 %, 15 %, 18 % 및 27 %의 배합비로 배합하여 본 발명의 기능성 조성물을 제조하였다.Functional composition of the present invention by combining the guava leaf, green tea, mugwort, aloe and grape seed water-soluble extract prepared in Example 1 in a blending ratio of 25%, 15%, 15%, 18% and 27%, respectively, based on the solid content% Was prepared.
실험예 1. 개개의 식물 추출물의 항산화 효과 측정Experimental Example 1 Determination of Antioxidant Effects of Individual Plant Extracts
본 발명의 실시예 1에서 제조한 각각의 식품 추출물과 실시예 2에서 제조한 기능성 조성물의 항산화 효능을 확인하기 위하여, 자유 라디칼인 1,1-디페닐-2-피 크릴히드라질(1,1-diphenyl-2-picrylhydrazyl; 이하 DPPH)을 이용하여 문헌에 기재된 실험 방법을 변형하여 실험을 수행하였다(Yasushi, S et al., Chem. Pharm. Bull. 47, pp1369, 1999). 2 × 10-4 M 농도가 되도록 에탄올에 용해시켜 제조한 DPPH 1.5 mL, 샘플 (1000 ppm - 10 ppm) 0.15 mL, 증류수 1.35 mL을 첨가하여 30분간 실온에서 반응시킨 후, 520 nm에서 흡광도를 UV-VIS spectrophotometer(Spectronic genesys 5, Milton Roy사, USA)를 이용하여 측정하였다. 본 발명 시료들의 DPPH 포착 효과는, 하기와 같은 수학식 1을 이용하여 계산된 DPPH 라디칼 포착활성을 구하여 비교하였다 (표1 - 표2). In order to confirm the antioxidant efficacy of each of the food extract prepared in Example 1 of the present invention and the functional composition prepared in Example 2, the free radical 1,1-diphenyl-2-picrylhydrazil (1,1 Experiments were performed by modifying the experimental method described in the literature using -diphenyl-2-picrylhydrazyl (hereinafter DPPH) (Yasushi, S et al., Chem. Pharm. Bull. 47, pp1369, 1999). After reacting at room temperature for 30 minutes by adding 1.5 mL of DPPH, 0.15 mL of sample (1000 ppm-10 ppm), and 1.35 mL of distilled water prepared by dissolving in ethanol to 2 × 10-4 M concentration, absorbance was UV at 520 nm. It was measured using a VIS spectrophotometer (
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (Acontrol-Bcontrol) × 100 = ((Acontrol-Bcontrol)-(Asample-Bsample)) / (Acontrol-Bcontrol) × 100
Acontrol : 시료를 첨가하지 않은 대조군의 흡광도Acontrol: Absorbance of the control group without sample
Asample : 시료를 첨가한 반응군의 흡광도Asample: Absorbance of reaction group with sample
Bcontrol : DPPH를 첨가하지 않은 대조군의 흡광도Bcontrol: absorbance of control group without DPPH
Bsample : DPPH를 첨가하지 않은 반응군의 흡광도Bsample: absorbance of reaction group without DPPH
그 결과, 하기 표 1에 나타낸 것과 같이 구아바잎, 녹차, 쑥, 알로에 및 포도씨의 수용성 추출물 모두 50 ppm 농도에서 DPPH 라디칼의 포착 효능이 60 % 이상 을 나타내었고, 녹차, 구아바잎, 쑥, 포도씨, 알로에 순으로 낮은 SC50값을 나타내어 우수한 항산화력을 지니고 있는 것으로 나타났다.As a result, as shown in Table 1 below, the water-soluble extracts of guava leaf, green tea, mugwort, aloe and grape seed all exhibited 60% or more of DPPH radical capture potency at 50 ppm, and the green tea, guava leaf, mugwort, grape seed, The low SC50 values in aloe were found to be excellent antioxidants.
실험예 2. 본 발명의 기능성 조성물의 DPPH 포착 효과Experimental Example 2 DPPH capture effect of the functional composition of the present invention
실시예 2에서 제조된 본 발명의 기능성 조성물과, 양성 대조군으로 비타민 E(Sigma사, USA, T-3251), (±)-카테친((±)-Catechin; Sigma사, USA, C-1788), 베타-카로틴(β-Carotene; Sigma사, USA, C-4582), 아스타산신 (Astaxanthin; Sigma사, USA, A-9335)에 대하여 위와 동일한 방법으로 DPPH를 이용한 자유라디칼 포착 효과를 SC50값으로 구하여 비교하였다. Functional composition of the present invention prepared in Example 2, and vitamin E (Sigma, USA, T-3251), (±) -catechin ((±) -Catechin; Sigma, USA, C-1788) as a positive control , Β-Carotene (β-Carotene; Sigma, USA, C-4582), Astaxanthin (Sigma, USA, A-9335), the same as above, free radical capture effect using DPPH as SC50 value Obtained and compared.
실험 결과, 본 발명의 실시예 2에서 제조된 기능성 조성물이 (±)-카테친보다는 낮은 항산화 효능을 나타내었으나 그 외 양성대조군으로 사용된 비타민 E, 베타-카로틴, 아스타산틴보다는 우수한 항산화력을 지니고 있음을 확인할 수 있었다 (표 3).Experimental results showed that the functional composition prepared in Example 2 of the present invention exhibited lower antioxidant efficacy than (±) -catechin, but had better antioxidant power than vitamin E, beta-carotene, and astaxanthin used as other positive controls. It could be confirmed (Table 3).
실험예 3. 본 발명의 기능성 조성물의 슈퍼옥사이드 음이온 라디칼 포착 효과Experimental Example 3. Superoxide Anion Radical Capture Effect of Functional Composition of the Present Invention
슈퍼옥사이드 음이온(anion) 라디칼 소거 효과 측정은 슈퍼옥사이드 디스무타제(Superoxide dismutase; SOD) 활성 검출 키트 (435-70601, Wako사, Japan) 방법을 변형하여 사용하였다.Superoxide anion radical scavenging effect measurement was used by modifying the method of Superoxide dismutase (SOD) activity detection kit (435-70601, Wako, Japan).
실시예 2의 기능성 조성물 및 양성대조군의 시료 0.05 mL(500 ppm - 10 ppm), 발색용액 (0.4 mM 크산틴(xanthin) + 0.1 M 인산염완충용액(phosphate buffer, pH 8.0) + 0.24 mM 니트로블루테트라졸리움(nitroblue tetrazolium; NO2-TB)) 0.5 mL, 효소액 (0.048 unit/mL 크산틴옥시데이즈(xanthine oxidase, from Butter milk) 용액 + 0.1 M 인산염완충용액(pH 8.0)) 0.5 mL를 첨가하고 잘 혼합하여 37 ℃에서 20 분간 반응시킨 후, 반응정지액 (709 mM 소디움도데실 설페이트(sodium dodecyl sulfate)) 1 mL를 첨가하여 효소반응을 정지시키고 560 nm에서 그 흡광도를 UV-VIS spectrophotometer(spectronic genesys 5, Milton Roy사, USA)를 이용하여 측정하였다. 본 실험에 사용된 양성 대조군으로는 비타민 E, (±)-카테친, 베타-카로틴, 아스타산틴을 사용하였고, 자세한 실험방법은 하기 표 4와 같으며, 슈퍼옥사이드 음이온 라디칼 포착 효과는 하기 수학식 2와 같이 계산하여 SC50값으로 비교하여 하기 표 5에 나타내었다.0.05 mL (500 ppm-10 ppm) of the functional composition of the Example 2 and the sample of the positive control, the coloring solution (0.4 mM xanthin + 0.1 M phosphate buffer (pH 8.0) + 0.24 mM nitroblue tetra Add 0.5 mL of nitroblue tetrazolium (NO2-TB), 0.5 mL of enzyme solution (0.048 unit / mL xanthine oxidase, from Butter milk solution + 0.1 mL of 0.1 M phosphate buffer (pH 8.0) and mix well The reaction was stopped at 37 ° C. for 20 minutes, and then 1 mL of reaction stop solution (709 mM sodium dodecyl sulfate) was added to stop the enzymatic reaction and the absorbance at 560 nm was measured by UV-VIS spectrophotometer (spectronic genesys 5). , Milton Roy, USA). As a positive control used in this experiment, vitamin E, (±) -catechin, beta-carotene, astaxanthin was used, the detailed experimental method is shown in Table 4 below, the superoxide anion radical capture effect is represented by
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (Acontrol-Bcontrol) × 100= ((Acontrol-Bcontrol)-(Asample-Bsample)) / (Acontrol-Bcontrol) × 100
하기 표 5에서 볼 수 있는 것처럼, 실시예 2의 기능성 조성물이 슈퍼옥사이드 음이온 라디칼에 대하여 가장 우수한 포착 효과를 나타내었고, 자세하게는 양성대조군으로 사용한 (± )-카테친보다는 1.63배, 아스타산틴보다는 약 10.34배 높은 효과를 나타내었으며, 비타민 E와 베타-카로틴은 슈퍼옥사이드 음이온 라디칼 포착 효과를 거의 나타내지 못하였다.As can be seen in Table 5 below, the functional composition of Example 2 showed the best capture effect on the superoxide anion radical, in particular 1.63 times than the (±) -catechin used as a positive control, about 10.34 than astaxanthin. The effect was twice as high, and vitamin E and beta-carotene showed little effect of trapping superoxide anion radicals.
실험예 4. 본 발명의 기능성 조성물의 지질과산화 억제 효과 측정 Experimental Example 4 Measurement of Lipid Peroxidation Inhibitory Effect of Functional Composition of the Present Invention
본 발명의 기능성 조성물의 지질과산화 억제능을 확인하기 위하여, 티오시안산염 철(ferric-thiocyanate; FTC) 방법을 이용한 지질과산화 억제 효과실험을 문헌(Takeshi et al, Food Chemistry, 75, pp237-40, 2001)에 기재된 실험 방법을 응용하여 사용하였다. In order to confirm the lipid peroxidation inhibitory ability of the functional composition of the present invention, a study on the effect of inhibiting lipid peroxidation using ferric-thiocyanate (FTC) method (Takeshi et al, Food Chemistry , 75 , pp237-40, 2001 The experimental method described in () was applied and used.
실시예 2에서 제조된 기능성 조성물 및 양성대조군 각 시료 (250 ppm) 0.2 mL, 0.2 M 인산나트륨염 완충용액(sodium phosphate buffer, pH 7.0) 0.5 mL, 에탄올로 용해한 2.5 % 리놀산(linoleic acid) 0.5 mL, 0.1 M 2,2'-아조비스-2-아미디노프로판-디하이드로클로라이드(2,2'-Azobis-2-amidinopropane-dihydrochloride; 이하 AAPH) 50 ㎕를 혼합한 후, 37 ℃ 암소에서 반응시키면서 200분 후에 반응중인 시료 용액 0.1 mL에 75 % 에탄올 9.7 mL, 30 % 암모니움티오시안산염(ammonium thiocyanate) 0.1 mL, 3.5 % 염산용액(HCl)으로 용해한 20 mM 염화제일철(FeCl2) 0.1 mL을 첨가하여 3분 동안 잘 혼합한 뒤 500 nm에서 흡광도를 UV-VIS spectrophotometer(spectronic genesys 5, Milton Roy사, USA)를 이용하여 측정하였다. 양성 대조군으로는 비타민 E, (± )-카테친, 베타-카로틴, 아스타산틴을 사용하였다. 지질과산화 억제 활성 (%)은 하기 수학식 3을 이용하여 계산하였다.0.2 mL of the functional composition prepared in Example 2 and each positive control sample (250 ppm), 0.5 mL of 0.2 M sodium phosphate buffer (pH 7.0), 0.5 mL of 2.5% linoleic acid dissolved in ethanol 50 μl of 0.1
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (Acontrol-Bcontrol) × 100= ((Acontrol-Bcontrol)-(Asample-Bsample)) / (Acontrol-Bcontrol) × 100
Acontrol : 시료를 첨가하지 않은 대조군의 흡광도Acontrol: Absorbance of the control group without sample
Asample : 시료를 첨가한 반응군의 흡광도Asample: Absorbance of reaction group with sample
Bcontrol : 리놀산을 첨가하지 않은 대조군의 흡광도Bcontrol: absorbance of control group without linoleic acid
Bsample : 리놀산을 첨가하지 않은 반응군의 흡광도Bsample: absorbance of reaction group without linoleic acid added
그 결과, 실시예 2의 기능성 조성물이 양성 대조군으로 사용한 비타민 E, (±)-카테친, 베타-카로틴, 아스타산틴의 억제효능에 비하여 각각 16 %, 29 %, 56 %, 76 % 더 높은 억제 효능을 나타내었다(표 6 참조).As a result, the functional composition of Example 2 was 16%, 29%, 56%, 76% higher inhibitory effect than the inhibitory effects of vitamin E, (±) -catechin, beta-carotene and astaxanthin, respectively, used as the positive control. (See Table 6).
실험예 5. 본 발명의 기능성 조성물의 하이드록시 라디칼 포착 효과 측정Experimental Example 5. Determination of the hydroxy radical trapping effect of the functional composition of the present invention
본 발명의 실시예 2의 기능성 조성물의 하이드록시 라디칼 포착 효과를 확인하기 위하여 하이드록시 라디칼로 인한 2-데옥시리보즈(2-Deoxyribose)의 산화 저해율을 측정하는 실험 문헌(Takeshi et al., Food Chemistry, 80, pp29-33, 2003)의 방법을 변형하여 사용하였다.In order to confirm the hydroxy radical scavenging effect of the functional composition of Example 2 of the present invention, an experimental document for measuring the oxidation inhibition rate of 2-deoxyribose due to hydroxy radicals (Takeshi et al., Food Chemistry , 80 , pp29-33, 2003).
먼저, 10 mM 황산제일철(FeSO4)-EDTA 150 ㎕, 10 mM 2-데옥시리보즈 150 ㎕, 실시예 2의 기능성 조성물 또는 양성대조군 시료용액 (10,000 ppm 또는 1,000 ppm) 300 ㎕, 0.2 M 인산나트륨염 완충용액(sodium phosphate buffer, pH 7.0) 450 ㎕, 10 mM 과산화수소(H2O2) 150 ㎕, 증류수 300 ㎕를 첨가하였다. 이 반응은 H2O2를 첨가함으로써 반응이 시작된다. 37 ℃에서 4시간 반응시킨 후 2.8 % 트리클로로아세트산(trichloro-acetic acid) 750 ㎕와 1.0 % 트리바비튜릭산(tribarbituric acid) 750 ㎕를 첨가하여 반응을 중지시키고 10분간 가열한 후, 얼음이 있는 상태에서 5분간 방치한 후 520 nm에서 흡광도를 UV-VIS spectrophotometer(spectronic genesys 5, Milton Roy사, USA)를 이용하여 측정하였다. 이 때, 양성 대조군으로는 비타민 E, (±)-카테친, 베타-카로틴, 아스타산틴을 사용하였으며 하이드록시 라디칼 포착 효과는 하기 수학식 4를 이용하여 계산하였다.First, 150 μl of 10 mM ferrous sulfate (FeSO4) -EDTA, 150 μl of 10 mM 2-deoxyribose, 300 μl of the functional composition or positive control sample solution of Example 2 (10,000 ppm or 1,000 ppm), 0.2 M sodium phosphate 450 μl of salt phosphate buffer (pH 7.0), 150 μl of 10 mM hydrogen peroxide (H 2 O 2), and 300 μl of distilled water were added. The reaction is initiated by adding H 2
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (Acontrol-Bcontrol) × 100= ((Acontrol-Bcontrol)-(Asample-Bsample)) / (Acontrol-Bcontrol) × 100
Acontrol : 시료를 첨가하지 않은 대조군의 흡광도Acontrol: Absorbance of the control group without sample
Asample : 시료를 첨가한 반응군의 흡광도Asample: Absorbance of reaction group with sample
Bcontrol : 과산화수소를 첨가하지 않은 대조군의 흡광도Bcontrol: absorbance of control group without hydrogen peroxide
Bsample : 과산화수소를 첨가하지 않은 반응군의 흡광도Bsample: absorbance of reaction group without hydrogen peroxide
그 결과, 하기 표 7에서 볼 수 있는 것처럼, 실시예 2의 기능성 조성물은 2,000 ppm과 200 ppm에서 양성대조군보다 높은 억제 효과를 나타내었다.As a result, as can be seen in Table 7, the functional composition of Example 2 showed a higher inhibitory effect than the positive control at 2,000 ppm and 200 ppm.
이상의 4가지 활성산소에 대한 항산력 측정 결과, 각각의 양성 대조군은 몇 종류의 활성 산소를 선택적으로 억제할 뿐 여러 형태의 활성산소를 동시에 억제하지는 못하는 것으로 나타났다. 그러나 실시예 2의 기능성 조성물은 높은 항산화력을 보유할 뿐만 아니라 여러 형태의 활성산소를 동시에 억제하며, 특히 활성산소 대사 메카니즘에서 가장 강한 형태의 활성산소이자 노화와 암의 주범인 하이드로시 라디칼에 대하여 강한 억제능을 가지고 있어 활성산소로 야기되는 여러 질병에 대하여 인체를 보호할 수 있을 것을 사료된다. 그러나 실시예 2의 기능성 조성물은 높은 항산화력을 보유할 뿐만 아니라 여러 형태의 활성산소를 동시에 억제하며, 특히 활성산소 대사 메카니즘에서 가장 강한 형태의 활성산소이자 피부 노화의 주범인 하이드로시 라디칼에 대하여 강한 억제능을 가지고 있어 활성산소로 야기되는 피부노화에 대하여 예방 및 개선을 할 수 있을 것으로 사료된다.As a result of measuring the antioxidant power of the four active oxygen, it was found that each positive control group selectively inhibited several kinds of active oxygen, but did not simultaneously inhibit several types of active oxygen. However, the functional composition of Example 2 not only retains high antioxidant power but also simultaneously inhibits various forms of free radicals, and particularly with respect to the hydroxy radical, which is the strongest form of free radicals in active oxygen metabolism mechanisms and the main culprit of aging and cancer. It is considered to have a strong inhibitory ability to protect the human body against various diseases caused by free radicals. However, the functional composition of Example 2 not only retains high antioxidant power but also simultaneously inhibits various forms of free radicals, and is particularly strong against the hydroxy radicals, which are the strongest forms of free radicals in the free radical metabolism mechanism and the main culprit of skin aging. It is thought to be able to prevent and improve skin aging caused by free radicals due to its inhibitory ability.
실험예 6. 본 발명의 기능성 조성물의 호염증성 싸이토카인 Interleukin-8 생산 억제능 측정Experimental Example 6. Measurement of inhibitory ability of basophilic cytokine Interleukin-8 production of the functional composition of the present invention
본 발명의 기능성 조성물의 하이드록시 라디칼 소거 효과를 확인하기 위하여 실시예 2의 기능성 조성물에 대해 항염증 효과를 측정하였다. 일반적으로 human monocyte인 THP-1 세포는 외부자극물질인 LPS(Lipopolysaccharide) 에 의해 호염증성 싸이토카인인 Interleukin-8을 세포 밖으로 분비한다. IL-8은 염증을 유발하는 싸이토카인으로 알려져 있어 THP-1 세포에 의한 IL-8 생산 증감 여부를 통해 항 염증 효과 여부를 판단할 수 있는데, IL-8의 농도가 적을수록 항염증 효과가 있는 것으로 판단한다.In order to confirm the hydroxy radical scavenging effect of the functional composition of the present invention, the anti-inflammatory effect of the functional composition of Example 2 was measured. In general, THP-1 cells, which are human monocytes, secrete out of the cell the inter-inflammatory cytokines Interleukin-8 by LPS (Lipopolysaccharide). IL-8 is known to be an inflammation-inducing cytokine, and it can be judged whether it is anti-inflammatory effect by increasing or decreasing IL-8 production by THP-1 cells. To judge.
먼저, P35 dish에 배양된 세포를 24시간 후 시험시료(적정농도)와 혼합된 배지로 교환한 후, 24시간 동안 배양 후 사용된 배지를 시료로 사용한다. 그리고 시료를 적정농도로 희석 후 IL-8 microplate 각 well에 넣은 후 반응시킨 다음, Conjugate을 넣고 일정시간 후 substrate로 반응 시킨 후 흡광도(A550 nm)를 측정하고 표준곡선에 따른 IL-8의 농도를 계산한다.First, the cells cultured in a P35 dish are replaced with a medium mixed with a test sample (titration) after 24 hours, and then the medium used after the culture for 24 hours is used as a sample. After diluting the sample to the appropriate concentration, put it into each well of IL-8 microplate, and then reacting. After adding Conjugate and reacting with the substrate after a certain time, absorbance (A550 nm) was measured and the concentration of IL-8 according to the standard curve was measured. Calculate
그 결과, 하기 표 8에서 볼 수 있는 것처럼, 실시예 2의 기능성 조성물은 시험물질이 함유되지 않은 대조군과 비교하여 최고 5% 농도를 사용한 실험군 1에서 IL-8의 생성이 약 50~60 % 감소함으로 기능성 조성물이 탁월한 항염증효과를 갖고 있는 것으로 확인되었다. As a result, as can be seen in Table 8, the functional composition of Example 2 reduced the production of IL-8 by about 50-60% in
실험예 7. 본 발명의 기능성 조성물의 콜라겐 생성능 및 콜라게네이즈(collagenase) 합성능 측정Experimental Example 7 Measurement of Collagen Formation Capacity and Collagenase Synthesis Capacity of Functional Compositions of the Present Invention
본 발명의 기능성 조성물의 콜라겐 생성능을 확인하기 위하여 실시예 2의 기능성 조성물에 대해 섬유아세포를 이용하여 타입 I 프로콜라겐(procollagen) 생성능을 측정하였다. 콜라겐 생성능 비교를 위하여 48-well 플레이트(plate)에 섬유아세포를 5 x 104 / well로 넣고 부착시킨 상태에서 준비된 기능성 조성물을 10~100 ppm 농도로 처리하였다. 24시간 배양한 후, 배양 상층액에서 타입 I 프로콜라겐 생성량을 타입 I pN 콜라겐 EIA kit를 이용하여 측정하였다. 측정된 타입 I 프로콜라겐 생성량을 총단백질량으로 나누어서 보정한 후, 대조군으로 별도의 시료를 첨가하지 않은 군, 비타민 C 처리군 및 TGF-b 처리군과 비교하여 그 결과를 표9에 나타내었다.Type I procollagen production ability was measured using fibroblasts for the functional composition of Example 2 to confirm the collagen production ability of the functional composition of the present invention. For comparison of collagen production ability, the prepared functional composition was treated at a concentration of 10 to 100 ppm in a state in which fibroblasts were placed at 5 x 10 4 / well in a 48-well plate. After incubation for 24 hours, the type I procollagen production in the culture supernatant was measured using a type I pN collagen EIA kit. After measuring the type I procollagen production by dividing the total protein mass, the results are shown in Table 9 compared with the group without the addition of a separate sample, the vitamin C treated group and the TGF-b treated group.
콜라게네이즈 합성 억제능 측정을 위하여 48-well 플레이트(plate)에 섬유아세포를 5 x 104 / well로 넣고 부착시킨 상태에서 UVB의 15 mJ/cm2를 조사한 후에 실시예 2의 기능성 조성물을 500 ppm 농도로 처리하였다.24시간 배양한 후, 배양 상층액에서 콜라게네이즈의 일종인 MMP-1(matrix metalloproteinases-1)의 생성량을 MMP-1 ELISA 키트를 이용하여 측정하였다. 측정된 MMP-1 발현양을 셀(cell)의 총단백질양으로 나누어서 보정한 후, 대조군으로 이용된 레티오익산(retinoic acid)과 TGF-b 처리군과 비교하여 그 결과를 표9에 나타내었다.In order to measure collagenase synthesis inhibitory activity, 15 mJ / cm2 of UVB was irradiated with fibroblasts attached to a 48-well plate at 5 × 10 4 / well, and then the functional composition of Example 2 was concentrated at 500 ppm. After 24 hours of incubation, the amount of production of collagenase matrix metalloproteinases (MMP-1) in the culture supernatant was measured using an MMP-1 ELISA kit. The measured MMP-1 expression amount was divided by the total protein amount of the cell, and then corrected. The results are shown in Table 9 compared with the retinoic acid and TGF-b treated groups used as controls. .
그 결과, 상기 표 9에서 볼 수 있는 것처럼, 섬유아세포에 실시예 2의 기능성 조성물을 처리시 콜라겐 합성이 증가하며 콜라겐을 분해하는 콜라게네이즈 생성이 감소함을 알 수 있다. 즉, 변성이 적고 바로 복용이 가능한 생약 추출물이면서도 불안정한 비타민C 또는 레티노익산에 상응하는 효과를 유지할 수 있다.As a result, as can be seen in Table 9, it can be seen that the collagen synthesis increases and collagenase production that degrades collagen decreases when fibroblasts are treated with the functional composition of Example 2. In other words, it is possible to maintain a corresponding effect to the unstable vitamin C or retinoic acid, which is a denatured and readily available herbal extract.
실험예 8. 본 발명의 기능성 조성물의 피부노화 방지 효과 측정시험Experimental Example 8. Measurement test of the anti-aging effect of the functional composition of the present invention
본 발명의 기능성 조성물의 피부노화 방지 효과를 측정하기 위해 인체 정상 섬유아세포(한국세포주은행)의 증식효과를 MTT 방법으로 측정하였다. 이 MTT 방법은 살아있는 세포의 미토콘드리아에 있는 mitochondrial dehydrogenase에 의해 MTT dye (3-(4,5)-dimethylthiazol- 2-yl)-2,5-diphenyl-tetrazolium bromide)가 blue formazan을 형성하는 것을 이용한 것으로 이 청색량이 미토콘드리아의 양이나 대사 활성을 나타내는 것이다. 96-well 플레이트(plate)에 섬유아세포를 1 x 104 / well로 넣고 부착시킨 상태에서 준비된 기능성 조성물을 100~10,000 ppm 농도로 처리하였다. 24시간 배양한 후, PBS에 용해한 MTT 용액 (5 μg/mL)을 가하고, CO2 incubator에서 2시간 방치한 다음 상등액을 제거한 뒤 DMSO : EtOH (1:1 v/v)를 well 당 100 μL씩 넣고 20분간 shaking한 다음, ELISA reader(VersaMax, Molecular device사, USA)로 570 nm에서 흡광도를 측정하였다. 대조군으로 별도의 시료를 첨가하지 않은 군과 기능성 조성물 처리군을 비교하였으며 그 결과, 대조군 대비 기능성 조성물 처리군의 세포 증식율이 1.3배 더 높은 것으로 나타냈다. 따라서 실시예 2의 기능성 조성물을 처리 시 세포증식 효능이 우수한 것을 알 수 있다.In order to measure the anti-aging effect of the functional composition of the present invention, the proliferative effect of human normal fibroblasts (Korea Cell Line Bank) was measured by MTT method. This MTT method uses MTT dye (3- (4,5) -dimethylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide) to form blue formazan by mitochondrial dehydrogenase in mitochondria of living cells. This blue amount represents the amount of mitochondria and metabolic activity. Fibroblasts were placed in a 96-well plate at 1 × 10 4 / well and attached to the prepared functional composition at a concentration of 100 to 10,000 ppm. After 24 hours of incubation, MTT solution (5 μg / mL) dissolved in PBS was added, left in a CO2 incubator for 2 hours, and then the supernatant was removed. After shaking for 20 minutes, the absorbance was measured at 570 nm with an ELISA reader (VersaMax, Molecular device, USA). The control composition was compared with the group that did not add a separate sample as a control group, and as a result, the cell growth rate of the functional composition treatment group was 1.3 times higher than that of the control group. Therefore, it can be seen that the cell proliferation efficacy is excellent when the functional composition of Example 2 is treated.
측정값을 하기의 수학식 1에 대입하여 세포 증식 효과를 산출하고, 그 결과는 하기 표 10에 나타내었다.The measured values were substituted into
상기 표 10에서 알 수 있듯이, 기능성 조성물을 처리하지 않은 대조군과 비교하여, 기능성 조성물이 처리된 실험군의 경우 매우 높은 섬유아세포 증식 효과를 나타낸다.As can be seen in Table 10, compared to the control group not treated with the functional composition, the experimental group treated with the functional composition shows a very high fibroblast proliferation effect.
실험예 9. 본 발명의 기능성 조성물의 티로시나제 활성에 대한 효과 측정Experimental Example 9. Determination of the effect on tyrosinase activity of the functional composition of the present invention
본 발명의 기능성 조성물의 미백효과를 측정하기 위하여 티로시나제 활성 억제효능의 정도를 측정하였다. 티로시나제는 생체 내에서 티로신이라는 물질이 산화되는 과정을 촉진하여 멜라닌이 생성되게 도와주는 효소이다. 이 효소의 기능을 억제하여 티로신이 산화되어 멜라닌이라는 흑색 고분자를 형성하는 것을 억제하는 정도를 보는 방법을 이용하여 미백효과를 측정하였다. 티로시나제에 대한 저해 활성은 시료 15 μL를 96-well에 넣고, 0.1 M 인산 완충액(pH 6.86) 150 μL, 1.5 mM 엘-티로신 용액 25 μL를 넣은 후, 2,380 units/mL 머쉬룸 티로시나제(0.05 M 인산완충용액, pH 6.86) 7 μL를 첨가하여 30℃에서 10분간 반응시킨 후, 475 nm에서 흡광도를 측정하였다. 티로시나제에 대한 저해율(%)은 수학식 6에 의하여 계산하였다.In order to measure the whitening effect of the functional composition of the present invention, the degree of inhibitory effect of tyrosinase activity was measured. Tyrosinase is an enzyme that accelerates the process of oxidation of a substance called tyrosine in the body, helping to produce melanin. The whitening effect was measured using a method of inhibiting the function of this enzyme to inhibit the oxidation of tyrosine to form a black polymer called melanin. Inhibitory activity against tyrosinase was determined by adding 15 μL of sample to 96-well, 150 μL of 0.1 M phosphate buffer (pH 6.86), 25 μL of 1.5 mM L-tyrosine solution, and then 2,380 units / mL mushroom tyrosinase (0.05 M phosphate buffer). Solution, pH 6.86), 7 μL was added and reacted at 30 ° C. for 10 minutes, and then the absorbance was measured at 475 nm. Inhibition rate for tyrosinase (%) was calculated by the equation (6).
A : 시료, 효소, 기질을 모두 첨가한 샘플의 흡광도A: Absorbance of the sample to which the sample, the enzyme, and the substrate are added
B : 시료, 기질만 첨가한 샘플의 흡광도B: absorbance of the sample and the sample added only the substrate
C : 효소, 기질만 첨가한 샘플의 흡광도C: absorbance of the sample added with enzyme and substrate only
도 1에서 나타난바와 같이, 본 발명의 기능성 조성물의 티로시나제 활성 저해효과를 측정한 결과, 실시예 2의 기능성 조성물은 현재 기능성 미백제로 사용되 고 있는 알부틴(Arbutin)보다 높은 저해활성을 나타내었다.As shown in FIG. 1, as a result of measuring the inhibitory effect of tyrosinase activity of the functional composition of the present invention, the functional composition of Example 2 showed higher inhibitory activity than arbutin currently used as a functional whitening agent.
실험예 10. 본 발명의 기능성 조성물의 엘라스타제 활성에 대한 효과 측정Experimental Example 10 Determination of the Effect on the Elastase Activity of the Functional Compositions of the Present Invention
본 발명의 기능성 조성물의 주름 개선효과를 측정하기 위하여 피부의 탄력도를 저해시키는 엘라스타제(Elastase)의 활성을 억제시키는 효과를 시험하였다. 시험방법은 피부노화 방지 측면의 in vitro 측정의 한 방법으로서, 피부탄력 유지에 중요한 역할을 하는 엘라스틴을 분해하는 체내 효소 엘라스타제를 저해하는 억제하는 방법이다. In order to measure the anti-wrinkle effect of the functional composition of the present invention, the effect of inhibiting the activity of elastase that inhibits the elasticity of the skin was tested. The test method is an in vitro measure of skin aging prevention and inhibits the enzyme elastase in the body that degrades elastin, which plays an important role in maintaining skin elasticity.
엘라스타제가 합성기질인 N-Suc-(Ala)3-ρ-nitroanilide를 분해하면 ρ-nitroanilide을 만드는데 이것이 노란색을 발색하게 한다. 이 발색정도를 흡광 광도계로 측정하여 엘라스타제 저해율을 계산하였다. 먼저, 0.2 M Tris-HCl 완충용액(pH 8.0)에 1 unit/100 μL 엘라스타제(porcine pancretic elastase)와 실시예 2의 기능성 조성물을 테스트 튜브에 넣고 15분간 25 ℃에서 예비 배양한 다음, 기질로 0.85 mM N-Suc-(Ala)3-ρ-nitroanilide 20 μL를 넣어 25 ℃에서 20 분간 반응시킨 후 405 nm에서 흡광도를 측정하여 기질로부터 생성되는 ρ-nitroanilide의 양을 정량하였다. 엘라스타제 저해활성 1 unit는 분당 1 μmol의 ρ-nitroanilide을 생성하는 활성으로 하였고, 저해활성(%)은 수학식 7으로부터 계산하였다.When elastase decomposes the synthetic substrate N-Suc- (Ala) 3-ρ-nitroanilide, it produces ρ-nitroanilide, which gives it a yellow color. This degree of color development was measured with an absorbance photometer to calculate the elastase inhibition rate. First, 1 unit / 100 μL elastase (porcine pancretic elastase) and the functional composition of Example 2 were added to a test tube in 0.2 M Tris-HCl buffer (pH 8.0), followed by preincubation at 25 ° C. for 15 minutes. 20 μL of 0.85 mM N-Suc- (Ala) 3-ρ-nitroanilide was added and reacted at 25 ° C. for 20 minutes, and the absorbance was measured at 405 nm to quantify the amount of ρ-nitroanilide generated from the substrate. One unit of elastase inhibitory activity was used to generate 1 μmol of ρ-nitroanilide per minute, and the inhibitory activity (%) was calculated from Equation 7.
A : 효소를 첨가하여 반응한 샘플의 흡광도A: absorbance of the sample reacted with the addition of enzyme
B : 효소를 첨가하지 않고 반응한 샘플의 흡광도B: absorbance of the sample reacted without adding enzyme
C : 샘플을 첨가하지 않고 반응한 대조군의 흡광도C: absorbance of the control group reacted without adding sample
D : 샘플과 효소를 첨가하지 않고 반응한 대조군의 흡광도D: Absorbance of the control group reacted without adding sample and enzyme
본 발명의 기능성 조성물의 엘라스타제 활성 저해효과 측정한 결과, 표 11에서 나타난 바와 같이, 농도 의존적인 저해 양상을 보였는데 5,000 ppm 이상에서 50 %이상의 억제효과를 보였다. 이러한 결과로 보아 주름의 발생원인 중 하나인 엘라스타제 활성 저해 효능이 우수한 것으로 보아, 피부 잔주름의 발생을 억제시킬 수 있는 기능을 부여할 수 있음을 알 수 있었다. As a result of measuring the inhibitory effect of elastase activity of the functional composition of the present invention, as shown in Table 11, it showed a concentration-dependent inhibition pattern showed more than 50% of the inhibitory effect at 5,000 ppm or more. As a result, it can be seen that the effect of inhibiting elastase activity, which is one of the causes of wrinkles, is excellent, and it can be given a function to suppress the occurrence of skin wrinkles.
실험예 11. 동물 실험을 통한 독성 실험Experimental Example 11. Toxicity test through animal experiment
본 발명의 실시예 2의 기능성 조성물에 대한 독성 여부를 알아보기 위하여 샘타코(경기 오산시 서랑동, Korea)에서 공급받은 5주령 SD 랫트 (수컷(250 g, 5마리), 암컷(210 g, 5마리) 15마리를 각 대조군 5마리, 실험군 10마리로 하여 3 g/kg 농도로 1회 경구투여 하고 2주간 생존여부, 몸무게, 털의 윤기, 곤두선 상태, 배변상태 및 전체적인 움직임 등 종합적인 건강상태를 확인하였다.In order to determine the toxicity of the functional composition of Example 2 of the present invention 5-week-old SD rats (male (250 g, 5), female (210 g, 5) received from Samtako (Seorang-dong, Osan-si, Gyeonggi-do) 15 rats were administered orally at a concentration of 3 g / kg with 5 control groups and 10 experimental groups, and survived for 2 weeks for a total health condition including survival, weight, hairiness, bristle, bowel movement, and overall movement. It was confirmed.
상기 실험 결과, 실시예 2의 기능성 조성물을 경구 투여한 실험군 10마리 모두 생존하였고 건강상태가 양호하였으며 특이사항은 발견되지 않았다 (표 12참조).As a result of the above experiment, all 10 experimental groups orally administered the functional composition of Example 2 survived and were in good health and no specificity was found (see Table 12).
실험예 12. 임상실험Experimental Example 12. Clinical Trials
본 발명의 실시예 2의 기능성 조성물에 대한 컨디션,체질 및 피부상태 변화를 알아보기 위해, 40대의 정상여성으로 피부타입은 건성피부이며, 피부의 건조나 냉한 체질이 신경쓰이는 사람 23명을 대상으로 하루 약 500 mg (1회 2정, 1일 2회)씩 8주간 복용하게 하여 간이 임상 실험을 실시하였다 (도 2-3 참조).In order to examine the changes in the condition, constitution and skin condition of the functional composition of Example 2 of the present invention, the normal type of women in their 40s, dry skin, 23 people who care about dry skin or cold constitution About 500 mg (two tablets once a day, twice a day) were administered for 8 weeks for a simple clinical trial (see FIG. 2-3).
상기 실험 결과, 실험 대상 대부분이 컨디션 및 체질과 관련하여 식욕, 졸림, 눈의 피로 등 13가지 증상에 있어서 실시예 2의 기능성 조성물을 섭취시 개선효과를 보였으며, 피부 탄력 및 주름 등과 관련된 설문조사에서도 개선 효과를 보였다. As a result of the above experiments, most of the subjects showed improvement in ingestion of the functional composition of Example 2 in 13 symptoms such as appetite, drowsiness, and eye fatigue in relation to physical condition and constitution, and a survey related to skin elasticity and wrinkles, etc. Also showed an improvement effect.
본 발명의 복합생약 추출물을 포함하는 기능성 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.It describes an example of the formulation of the functional composition comprising the extract of the complex herbal of the present invention, the present invention is not intended to limit it, but is intended to explain in detail only.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
실시예 2의 기능성 조성물 300 mg300 mg of the functional composition of Example 2
유당 100 mg
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
실시예 2의 기능성 조성물 50 mg50 mg of the functional composition of Example 2
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
제제예 3. 캅셀제의 제조Formulation Example 3 Preparation of Capsule
실시예 2의 기능성 조성물 50 mg50 mg of the functional composition of Example 2
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예 4. 건강 식품의 제조Formulation Example 4 Preparation of Healthy Food
실시예 2의 기능성 조성물 1000 ㎎1000 mg of functional composition of Example 2
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 ㎎Vitamin C 10 mg
비오틴 10 ㎍10 μg biotin
니코틴산아미드 1.7 ㎎Nicotinic Acid 1.7 mg
엽산 50 ㎍50 μg folic acid
판토텐산 칼슘 0.5 ㎎Calcium Pantothenate 0.5mg
무기질 혼합물 적량Mineral mixture
황산제1철 1.75 ㎎Ferrous Sulfate 1.75 mg
산화아연 0.82 ㎎Zinc Oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dibasic calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium Citrate 90 mg
탄산칼슘 100 ㎎
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
제제예 7. 건강 음료의 제조Formulation Example 7 Preparation of Healthy Drink
실시예 2의 기능성 조성물 1000 ㎎1000 mg of functional composition of Example 2
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g oligosaccharides
매실농축액 2 gPlum concentrate 2 g
타우린 1 g1 g of taurine
정제수를 가하여 전체 900 ㎖Add 900 ml of purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.
한편, 본 발명은 기재된 실시예에 한정되는 것이 아니고, 본 발명의 사상 및 범위를 벗어나지 않고 다양하게 수정 및 변형을 할 수 있음은 이 기술 분야에서 통상의 지식을 가진 자에게는 자명하다. 따라서 그러한 변형예 또는 수정예들은 본 발명의 특허청구범위에 속한다 해야 할 것이다.On the other hand, the present invention is not limited to the described embodiments, it is obvious to those skilled in the art that various modifications and variations can be made without departing from the spirit and scope of the present invention. Therefore, such modifications or variations will have to belong to the claims of the present invention.
도 1은 본 발명의 실시예 2의 기능성 조성물의 티로시나제 저해활성 결과를 나타낸 도면,1 is a view showing the tyrosinase inhibitory activity results of the functional composition of Example 2 of the present invention,
도 2는 본 발명의 실시예 2의기능성 조성물을 섭취시 나타나는 컨디션 및 체질 변화를 나타낸 도면,Figure 2 is a view showing the condition and constitution changes appearing when ingesting the functional composition of Example 2 of the present invention,
도 3은 본 발명의 실시예 2의기능성 조성물을 섭취시 나타나는 피부상태의 변화를 나타낸 도면.3 is a view showing a change in skin condition appearing when ingesting the functional composition of Example 2 of the present invention.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090040461A KR20100121352A (en) | 2009-05-08 | 2009-05-08 | A composition comprising complex crude drug extract for anti-aging and improvement of skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090040461A KR20100121352A (en) | 2009-05-08 | 2009-05-08 | A composition comprising complex crude drug extract for anti-aging and improvement of skin |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20100121352A true KR20100121352A (en) | 2010-11-17 |
Family
ID=43406710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090040461A KR20100121352A (en) | 2009-05-08 | 2009-05-08 | A composition comprising complex crude drug extract for anti-aging and improvement of skin |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20100121352A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101454875B1 (en) * | 2012-09-27 | 2014-11-04 | 청운대학교산학협력단 | Bath agent containing artemisia annua |
US9662295B2 (en) | 2012-06-29 | 2017-05-30 | Amorepacific Corporation | Composition containing tea water for suppressing aging of skin |
KR20180066312A (en) * | 2016-12-07 | 2018-06-19 | 주식회사 지원바이오 | Method for optimal extraction of Camellia sinensis and Artemisia argyi mixture using response surface methodology |
KR20180123648A (en) * | 2018-11-08 | 2018-11-19 | (주)아모레퍼시픽 | Composition for skin moisturizing containing extract of soybean leaf |
KR101961152B1 (en) * | 2017-11-15 | 2019-03-25 | 주식회사 프롬바이오 | Food composition or cosmetics for whitening, moisturizing or anti-aging of skin with sheep placenta and plant complex |
-
2009
- 2009-05-08 KR KR1020090040461A patent/KR20100121352A/en not_active Application Discontinuation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9662295B2 (en) | 2012-06-29 | 2017-05-30 | Amorepacific Corporation | Composition containing tea water for suppressing aging of skin |
KR101454875B1 (en) * | 2012-09-27 | 2014-11-04 | 청운대학교산학협력단 | Bath agent containing artemisia annua |
KR20180066312A (en) * | 2016-12-07 | 2018-06-19 | 주식회사 지원바이오 | Method for optimal extraction of Camellia sinensis and Artemisia argyi mixture using response surface methodology |
KR101961152B1 (en) * | 2017-11-15 | 2019-03-25 | 주식회사 프롬바이오 | Food composition or cosmetics for whitening, moisturizing or anti-aging of skin with sheep placenta and plant complex |
KR20180123648A (en) * | 2018-11-08 | 2018-11-19 | (주)아모레퍼시픽 | Composition for skin moisturizing containing extract of soybean leaf |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20210087405A (en) | Compositions Containing Plant Extracts | |
KR101776071B1 (en) | Composition containing red sword bean extract for anti-aging and whitening | |
KR101059471B1 (en) | Cosmetic composition for skin aging | |
KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
CA2520057A1 (en) | Composition for promoting production of type i collagen and/or elastin | |
JP2011195504A (en) | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent | |
KR101936294B1 (en) | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata | |
KR20090080153A (en) | Composition for wrinkle-care and skin-whitening | |
KR20150050310A (en) | Composition for improving skin conditions comprising artemisiae annuae herba, neem leaf, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR20170137552A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20100121352A (en) | A composition comprising complex crude drug extract for anti-aging and improvement of skin | |
KR20170137553A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137564A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137544A (en) | Composition for improving skin condition comprising herb extracts mixture | |
JP2011195502A (en) | Fibroblast proliferation promoter, anti-ageing agent and wrinkle-ameliorating agent | |
KR102585685B1 (en) | Composition for protecting or improving UV-induced skin damage comprising the extract of plants as an active ingredient | |
KR20170137549A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136911A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136389A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR100596316B1 (en) | Composition of health functional food to support skin beauty and antiaging | |
KR20170136933A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20130054518A (en) | Food composition comprising algae extracts and the use thereof | |
KR20170137405A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136919A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102183896B1 (en) | Composition for improving skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |